News

BIO-CAT Gains Organic Certification to Meet the Growing Demands of Consumers

As consumer demand for clean-label, organic, and non-GMO products continues to surge, the pressure is mounting on ingredient suppliers to meet stringent certification standards and scale production accordingly.

As the “food as medicine” movement gains traction and shoppers report increasing their purchases of natural (23%) and organic (22%) products over the last six months, the message is clear: the future of food is clean, and suppliers must rise to the occasion—or risk being left behind*.

According to industry research, sales of natural, organic, and functional products grew by 6.6%, while conventional product sales declined by 0.2%**. This growth is largely driven by consumers prioritizing health, transparency, and sustainability. Organic and non-GMO certifications remain the top two attributes driving purchasing decisions—with 65% of shoppers stating they are more likely to buy a product that carries either the USDA Organic or Non-GMO Project Verified seal***.

This consumer demand is now aligning with policy, as the White House Administration echoes the need for increased access to organic options. “All Americans deserve access to clean, organic, healthy food for our families and children,” states the MAHA Action website. “Major food companies need to take accountability and responsibility for the ingredients that they put in our food and how they market their products to consumers.”

However, meeting this rapidly growing demand is no easy feat. Becoming organic certified requires a rigorous inspection process and adherence to strict federal standards prohibiting the use of synthetic pesticides, GMOs, and growth hormones. As brands shift toward clean formulations, ingredient suppliers are being called upon to deliver at scale—without compromising on integrity or quality.

Two companies rising to meet this challenge are BIO-CAT, Inc. (Troy, VA) and BIO-CAT Microbials, LLC (Shakopee, MN), both of which have successfully achieved Organic Certification through QAI (Quality Assurance International), a leading certification body under the USDA National Organic Program. This certification also extends to their branded products, OPTIZIOME P3 HYDROLYZER® from BIO-CAT, Inc. and OPTIBIOME BS50® from BIO-CAT Microbials, Inc.

“BIO-CAT is committed to producing top-quality products for our customers,” said Robert Boyd, Director of Compliance for both companies. “Achieving organic certification for our facilities is another level of quality that we have implemented into our operations, as well as for the ingredients we produce.”

As the leader in enzyme solutions and probiotic strain development and fermentation, BIO-CAT and BIO-CAT Microbials understand that this certification is critical for both their customers and to continue to demonstrate their leadership role in the industry. “BIO-CAT and BIO-CAT Microbials are proud to support the growing natural product movement with a robust portfolio of non-GMO enzymes and non-GMO microbials” stated Chris Schuler, CEO & Founder of BIO-CAT and BIO-CAT Microbials. “I look forward to our team sharing this information with the industry at Vitafoods Europe in Barcelona this week.”

Learn more here.

Recent News

11/18/2026

GeneDx Announces Leadership Transition

GeneDx (Nasdaq: WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today announced that its Board of Directors has appointed Everett Cunningham as Chief Executive Officer and a member of the Board, effective on or before December 15, 2026. Mr. Cunningham succeeds Katherine Stueland, who has announced that …

11/17/2026

LifeNet Health Announced that Rony Thomas has Resigned

LifeNet Health announced that Rony Thomas has resigned as President and Chief Executive Officer and as a member of its Board of Directors, effective November 13, 2026. Mr. Thomas led LifeNet Health since 2004. During his tenure, the organization grew into a global leader in organ and tissue procurement and regenerative medicine. “On behalf of …

11/10/2026

Luminoah Raises $25 Million Series B to Expand Access to Its FDA-Cleared Enteral Feeding System

Luminoah, a medical technology company modernizing enteral nutrition, today announced a $25 million Series B financing led by Sandbox Clinical Ventures, with participation from the Blue Venture Fund, GV (Google Ventures), Sands Capital, Texas Medical Center Venture Fund, the CU Healthcare Innovation Fund, the American Gastroenterological Association GI Opportunity Fund, and existing investors. The Series …